Fig. 1: Change in SARS-CoV-2 differential antibody response in an older-adult population across a 10-month period, London, UK, June 2020-April 2021. | Communications Medicine

Fig. 1: Change in SARS-CoV-2 differential antibody response in an older-adult population across a 10-month period, London, UK, June 2020-April 2021.

From: Hybrid immunity in older adults is associated with reduced SARS-CoV-2 infections following BNT162b2 COVID-19 immunisation

Fig. 1: Change in SARS-CoV-2 differential antibody response in an older-adult population across a 10-month period, London, UK, June 2020-April 2021.The alternative text for this image may have been generated using AI.

Vaccination of participants occurred in a two-dose Pfizer-BioNTech vaccine regimen split at 12 weeks and antibodies were then measured at 4 weeks after the second dose. Participants with missing data at any time point were not included in these alluvial plots. a n = 153 individual participants. Demonstrates change in SARS-CoV-2 anti-NP antibody seropositivity across the cohort measured at three time points between June 2020 and Apr 2021, b n = 122 individual participants. Demonstrates change in SARS-CoV-2 anti-RBD antibody seropositivity as measured by RBD DABA across the cohort measured at three time points between June 2020 and Apr 2021, c n = 148 individual participants. Demonstrates change in anti-RBD SARS-CoV-2 IgG antibody seropositivity as quantified by the Abbott SARS-CoV-2 IgG II Quant Assay across the cohort measured at three time points between June 2020 and Apr 2021. Only 54.3% of those initially anti-NP seropositive in June 2020 remained so in December 2020, reducing further to 38.6% by April 2021. In contrast, 93.5% of those seropositive of those anti-RBD seropositive in June remained so 6 months later in December 2020. Post-vaccine (April 2021) anti-RBD seropositivity increased to 98.9%.

Back to article page